TIL (Instil Bio, Inc.) Stock Financials & Earnings

TILInstil Bio, Inc.

Mkt Cap$62M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$75M

EPS (TTM)-$11.39

Free Cash Flow (TTM)-$40M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

▶Q3 2025

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyt...

CEO Bronson CrouchIPO Mar 19, 2021instilbio.com

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$0	$0	-$57M
Q1 23	$0	$0	-$58M
Q2 23	$0	$0	-$21M
Q3 23	$0	$0	-$67M
Q4 23	$0	-$1M	-$13M
Q1 24	$0	-$993K	-$20M
Q2 24	$0	$0	-$14M
Q3 24	$0	$0	-$24M
Q4 24	$0	-$741K	-$11M
Q1 25	$0	$0	-$31M
Q2 25	$0	$0	-$23M
Q3 25	$0	-$12K	-$15M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$37M	-$50M
Q1 23	-$35M	-$43M
Q2 23	-$20M	-$27M
Q3 23	-$14M	-$20M
Q4 23	-$13M	-$13M
Q1 24	-$14M	-$14M
Q2 24	-$11M	-$11M
Q3 24	-$20M	-$20M
Q4 24	-$11M	-$11M
Q1 25	-$4M	-$4M
Q2 25	-$15M	-$15M
Q3 25	-$11M	-$11M

Capital Expenditures

CapEx

Quarter	CapEx
Q4 22	$13M
Q1 23	$8M
Q2 23	$7M
Q3 23	$5M
Q4 23	$58K
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	—	+5.7%
Q1 23	—	+7.7%
Q2 23	—	-64.3%
Q3 23	—	+17.8%
Q4 23	—	-77.4%
Q1 24	—	-66.3%
Q2 24	—	-32.6%
Q3 24	—	-64.6%
Q4 24	—	-10.8%
Q1 25	—	+55.3%
Q2 25	—	+65.8%
Q3 25	—	-36.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$0	—
Q1 23	$5M	—
Q2 23	$4M	—
Q3 23	$5M	—
Q4 23	$5M	—
Q1 24	$5M	—
Q2 24	$4M	—
Q3 24	$4M	—
Q4 24	$5M	—
Q1 25	$3M	—
Q2 25	$2M	—
Q3 25	$2M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 22	$21M	$13M	—
Q1 23	$21M	$13M	—
Q2 23	$8M	$12M	—
Q3 23	$8M	$12M	—
Q4 23	$2M	—	$10M
Q1 24	$7M	$12M	—
Q2 24	$3M	$11M	—
Q3 24	$562K	$11M	—
Q4 24	$1M	—	$10M
Q1 25	$5M	$9M	—
Q2 25	$7M	$6M	—
Q3 25	$9M	$6M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$44M	$217M	$261M
Q1 23	$27M	$196M	$223M
Q2 23	$22M	$180M	$202M
Q3 23	$9M	$174M	$183M
Q4 23	$9M	$141M	$150M
Q1 24	$5M	$148M	$154M
Q2 24	$7M	$142M	$149M
Q3 24	$7M	$114M	$120M
Q4 24	$9M	$105M	$113M
Q1 25	$15M	$88M	$104M
Q2 25	$8M	$84M	$92M
Q3 25	$6M	$74M	$80M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	6M	-95.0%
Q1 23	7M	+0.2%
Q2 23	7M	+0.0%
Q3 23	7M	+0.0%
Q4 23	7M	-0.0%
Q1 24	7M	+0.0%
Q2 24	7M	+0.0%
Q3 24	7M	+0.0%
Q4 24	7M	+0.3%
Q1 25	7M	+0.1%
Q2 25	7M	+1.0%
Q3 25	7M	+2.4%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 19	—	—
FY 20	—	—
FY 21	$0	412
FY 22	$0	192
FY 23	$0	49
FY 24	$0	14